Compare · ADCT vs IMGN
ADCT vs IMGN
Side-by-side comparison of ADC Therapeutics SA (ADCT) and ImmunoGen Inc. (IMGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADCT and IMGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IMGN is the larger of the two at $1.15B, about 9.3x ADCT ($124.4M).
- ADCT has hit the wire 12 times in the past 4 weeks while IMGN has been quiet.
- ADCT has more recent analyst coverage (19 ratings vs 13 for IMGN).
- Company
- ADC Therapeutics SA
- ImmunoGen Inc.
- Price
- $1.01+3.13%
- $31.24+0.02%
- Market cap
- $124.4M
- $1.15B
- 1M return
- -71.00%
- -
- 1Y return
- -71.57%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- 1989
- News (4w)
- 12
- 0
- Recent ratings
- 19
- 13
ADC Therapeutics SA
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ImmunoGen Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Latest ADCT
- ADC Therapeutics downgraded by H.C. Wainwright
- ADC Therapeutics downgraded by RBC Capital Mkts with a new price target
- Director Azelby Robert was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 40% to 112,805 units (SEC Form 4) to cover withholding tax
- Director Squarer Ron was granted 45,000 shares and covered exercise/tax liability with 15,196 shares, increasing direct ownership by 32% to 123,431 units (SEC Form 4) to satisfy withholding obligation
- Director Sandor Victor was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 140,686 units (SEC Form 4) (tax withholding)
- Director Monges Viviane was granted 45,000 shares and covered exercise/tax liability with 2,596 shares, increasing direct ownership by 29% to 186,447 units (SEC Form 4) to cover withholding tax
- Director Hug Peter was granted 45,000 shares and covered exercise/tax liability with 2,156 shares, increasing direct ownership by 19% to 263,344 units (SEC Form 4) to cover withholding tax
- Director Bizzari Jean-Pierre was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 30% to 139,302 units (SEC Form 4) to satisfy withholding tax
- Director Coughlin Timothy was granted 45,000 shares and covered exercise/tax liability with 12,600 shares, increasing direct ownership by 81% to 72,400 units (SEC Form 4) (tax withholding)
- ADC Therapeutics SA filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest IMGN
- Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
- PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
- Seaport Therapeutics Names Lauren White as Chief Financial Officer
- March 26, 2024 - FDA Roundup: March 26, 2024
- FDA Approval for ELAHERE issued to IMMUNOGEN INC
- SEC Form 15-12G filed by ImmunoGen Inc.
- SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)
- SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)
- SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)
- Mitchell Dean J returned 103,000 shares to the company, closing all direct ownership in the company (SEC Form 4)